IL-STATS
Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere!
STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones.
“No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and players,” said Mike Rodriguez, Vice President of Account Management at STATS. “STATS Insights taps into our extensive historical database to uncover stories many fans may be missing. SpokeHub is a great fit to feature STATS Insights because it engages with soccer fans in ways no other social engagement platform can. We are excited to work with SpokeHub and look forward to seeing more in-depth World Cup conversations on its platform.”
The SpokeHub app features “Hubs” on the homepage that connect users with the content that is most relevant to them. Hubs bring together communities with real-time conversations around important trending topics, like World Cup moments for each national team. The app features built-in news and scoreboard updates and enhanced engagement features, including polls and the first-ever AR chat experience.
“With the World Cup being the largest sporting event in the world, SpokeHub is excited to partner with STATS to allow fans globally to connect and engage utilizing our chat technology. This partnership is a game changer to the World Cup fan experience as we know it – for the first time ever we are connecting fans around the world in one unified place.” – Robert Hartsfield, CEO of SpokeHub.
Fans looking for real World Cup engagement and impactful conversations can download the SpokeHub app in the Apple Store and Google Play .
About STATS
STATS is the global leader in sports intelligence, operating at the intersection of sports and technology. The world’s most innovative brands, technology companies, leagues and dozens of world championship teams trust STATS to find their winning edge. STATS combines the industry’s fastest and most accurate data platform with video analysis, sports content and research, player tracking through STATS SportVU®, and a range of customizable digital solutions for brands. The pioneer of live sports data, STATS continues to speed innovation in the industry enhancing both team performance and fan experience. For more information, go to www.stats.com and follow STATS on Twitter @STATSOnThePitch.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005398/en/
Contact:
STATS
Reed Findlay, 847-583-2642
mediarelations@stats.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 14:00:00 CET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 14:00:00 CET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 14:00:00 CET | Press release
Financing will support the company’s expansion across EMEA to keep pace with AI and cloud demand Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 13:57:00 CET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom